Anti-Sumo 1抗体(ab3819)

概述

  • 产品名称Anti-Sumo 1抗体
    参阅全部 Sumo 1 一抗
  • 描述
    兔多克隆抗体to Sumo 1
  • 经测试应用适用于: WBmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Recombinant full length protein (Human) corresponding to the full expressed region of the human Sumo 1 precursor.

  • 阳性对照
    • Sumo 1 fusion protein.
  • 常规说明


    This product can be used as part of an assay for sumoylation activity. Human Aos 1 + Uba 2 (ab3804), Ubc 9 (ab3803) and Sumo 1 (ab3801) can be used to promote in vitro sumoylation of a sumoylation marker (human Topoisomerase I protein fragment) (ab3828). The reaction products can be detected using our Sumo 1 (ab3819 and ab3824) and Topoisomerase I (ab3825) antibodies. Sumoylation assays are carried out in a final volume of 20µl in reaction conditions (20 mM Hepes pH 7.5, 5mM MgCl2, 2mM ATP). Sumoylation Protocol: 1. Prepare a suitable purified substrate protein. (For the control, use 2µl Topoisomerase I marker for each reaction.) 2. In each reaction, add 4µl E2 to substrate first, then 2µl Sumo 1, 2µl 10x reaction buffer, 2µl E1. Finally, add H2O to bring up to 20µl. We would recommend adding fresh 2mM ATP to be sure that sufficient energy is supplied. 3. The best reaction concentration of proteins is as following: Aos 1 + Uba 2: 7.5µg/ml. Ubc 9: 50µg/ml. SUMO 1: 50µg/ml. For the control assay we recommend running the assay at 37ºC for 30-60 minutes. 4. Detect the reaction products by Western blot using a suitable antibody. For the control reaction use 1/1000 dilution of the supplied Topoisomerase I antibody. Four sumoylated bands should be seen on the gel for the control reaction. This assay has been shown to work with crude extracts. Be aware that Uba 2 contains his-rich regions which might cross-react with antibodies against the 6x-His epitope tag. During western analysis with anti-6x-His antibodies, Uba 2 at 80 kDa might be shown.

性能

  • 形式Liquid
  • 存放说明Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • 存储溶液Preservative: None
    Constituents: Whole Serum
  • 纯度Whole antiserum
  • Primary antibody说明This product can be used as part of an assay for sumoylation activity. Human Aos 1 + Uba 2 (ab3804), Ubc 9 (ab3803) and Sumo 1 (ab3801) can be used to promote in vitro sumoylation of a sumoylation marker (human Topoisomerase I protein fragment) (ab3828). The reaction products can be detected using our Sumo 1 (ab3819 and ab3824) and Topoisomerase I (ab3825) antibodies. Sumoylation assays are carried out in a final volume of 20µl in reaction conditions (20 mM Hepes pH 7.5, 5mM MgCl2, 2mM ATP). Sumoylation Protocol: 1. Prepare a suitable purified substrate protein. (For the control, use 2µl Topoisomerase I marker for each reaction.) 2. In each reaction, add 4µl E2 to substrate first, then 2µl Sumo 1, 2µl 10x reaction buffer, 2µl E1. Finally, add H2O to bring up to 20µl. We would recommend adding fresh 2mM ATP to be sure that sufficient energy is supplied. 3. The best reaction concentration of proteins is as following: Aos 1 + Uba 2: 7.5µg/ml. Ubc 9: 50µg/ml. SUMO 1: 50µg/ml. For the control assay we recommend running the assay at 37ºC for 30-60 minutes. 4. Detect the reaction products by Western blot using a suitable antibody. For the control reaction use 1/1000 dilution of the supplied Topoisomerase I antibody. Four sumoylated bands should be seen on the gel for the control reaction. This assay has been shown to work with crude extracts. Be aware that Uba 2 contains his-rich regions which might cross-react with antibodies against the 6x-His epitope tag. During western analysis with anti-6x-His antibodies, Uba 2 at 80 kDa might be shown.
  • 克隆多克隆
  • 同种型IgG
  • 研究领域

应用

Our Abpromise guarantee covers the use of ab3819 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB 1/1000. Detects a band of approximately 12 kDa.

60 minute incubation at 25°C.

靶标

  • 功能Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development.
  • 疾病相关Defects in SUMO1 are the cause of non-syndromic orofacial cleft type 10 (OFC10) [MIM:613705]; also called non-syndromic cleft lip with or without cleft palate 10. OFC10 is a birth defect consisting of cleft lips with or without cleft palate. Cleft lips are associated with cleft palate in two-third of cases. A cleft lip can occur on one or both sides and range in severity from a simple notch in the upper lip to a complete opening in the lip extending into the floor of the nostril and involving the upper gum. Note=A chromosomal aberation involving SUMO1 is the cause of OFC10. Translocation t(2;8)(q33.1;q24.3). The breakpoint occurred in the SUMO1 gene and resulted in haploinsufficiency confirmed by protein assays.
  • 序列相似性Belongs to the ubiquitin family. SUMO subfamily.
    Contains 1 ubiquitin-like domain.
  • 翻译后修饰Cleavage of precursor form by SENP1 or SENP2 is necessary for function.
    Polymeric SUMO1 chains undergo polyubiquitination by RNF4.
  • 细胞定位Nucleus membrane. Nucleus speckle. Cytoplasm. Recruited by BCL11A into the nuclear body.
  • Information by UniProt
  • 数据库链接
  • 别名
    • DAP1 antibody
    • GAP modifying protein 1 antibody
    • GAP-modifying protein 1 antibody
    • GMP 1 antibody
    • GMP1 antibody
    • OFC10 antibody
    • PIC 1 antibody
    • PIC1 antibody
    • SENP2 antibody
    • Sentrin 1 antibody
    • Sentrin antibody
    • Small ubiquitin related modifier 1 antibody
    • Small ubiquitin-like modifier 1 antibody
    • Small ubiquitin-related modifier 1 antibody
    • SMT3 antibody
    • SMT3 homolog 3 antibody
    • SMT3 suppressor of mif two 3 homolog 1 antibody
    • SMT3, yeast, homolog 3 antibody
    • Smt3C antibody
    • SMT3H3 antibody
    • SUMO-1 antibody
    • SUMO1 antibody
    • SUMO1_HUMAN antibody
    • Ubiquitin homology domain protein PIC1 antibody
    • Ubiquitin Like 1 antibody
    • Ubiquitin like protein SMT3C antibody
    • Ubiquitin like protein UBL1 antibody
    • Ubiquitin-homology domain protein PIC1 antibody
    • Ubiquitin-like protein SMT3C antibody
    • Ubiquitin-like protein UBL1 antibody
    • UBL 1 antibody
    • UBL1 antibody
    see all

Anti-Sumo 1 antibody 图像

  • Left lane: Western blot (12.5% gel) of sumoylated Topo I protein with Topo I antibody T8N.

    Right lane: Western blot of sumoylated Topo I protein with ab3819.

    Both primaries were used a dilution of 1/1000 (60 minutes at 25°C).

    Topo I protein has multiple sumoylation sites. Four sumoylated Topo I can be seen by Topo I antibody and seven sumoylated Topo I can be seen by Sumo I antibody.

Anti-Sumo 1 antibody (ab3819)参考文献

ab3819 has not yet been referenced specifically in any publications.

Product Wall

Thank you for your email. Have you done a no primary control (incubate with your secondary antibody only) to ensure that the background is not due to the secondary antibody? You also may need to further dilute both the primary and secondary antibodies ...

Read More

Thank you for your email and I'm sorry to hear that you are experiencing difficulty with ab3819. Is your secondary antibody conjugated to HRP? Usually when you see a reverse image on the film it means that there is too much HRP in the system. You s...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"